Hot on the heels of the latest complete response letter from the US Food and Drug Administration over its AVT02 proposed rival to Humira (adalimumab), biosimilars specialist Alvotech has appointed a new chief quality officer, just six months after the last replacement.
After Latest Adalimumab CRL, Alvotech Gets Another New Quality Chief
Sarah Tanksley, Appointed In October, Replaced By Sandra Casaca At Biosimilars Firm
Six months after replacing its chief quality officer, biosimilars specialist Alvotech has again appointed a new head of quality, in the wake of the latest US FDA knockback for its AVT02 proposed adalimumab biosimilar rival to Humira.
More from Leadership
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
Fresenius Kabi is drawing closer to the conclusion of its Vision 2026 strategic roadmap. The company’s CEO, Pierluigi Antonelli, talks to Generics Bulletin about the company’s results so far and how it’s investments in biosimilars, acquisitions and manufacturing is paying off.
• By
IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.
More from Generics Bulletin
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
• By
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.